EuroBiotech: More Articles of Note


> Silenseed is trying to raise $10 million to fund a phase 2 pancreatic cancer trial. The trial will assess the efficacy of the Israeli biotech’s KRAS-targeting siRNA. Silenseed tried to raise money via a Nasdaq IPO in 2014 but aborted its attempt the following year. The company is also planning to combine its siRNA with an immunotherapy. Statement   

> Kamada priced a stock offering expected to gross about $15 million. The Israeli biotech plans to use the money to fund late-phase clinical trials. Release 

> ITeos Therapeutics secured a €7.5 million grant. The money equips iTeos to move its adenosine receptor A2A antagonist into the clinic. A trial of the cancer candidate is due to start in Belgium next year. Statement  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The United Kingdom outlined plans to create a National investment Fund. The vehicle is intended to ensure startups in life sciences and other industries have the cash they need to blossom, regardless of whether the U.K. cuts its ties to the European Investment Fund after Brexit. Release  

> Compugen named Paul Sekhri as its chairman. The appointment gives Compugen access to the experience and network of a life sciences veteran who has held senior positions at companies including Novartis, Sanofi and Teva. Statement

> Valneva appointed Wolfgang Bender, M.D., Ph.D., as its CMO. Bender joins Valneva after holding leadership positions in the medical affairs teams at Takeda and Novartis’ vaccine units. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.